Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program

Prelaj, A; Bottiglieri, A; Proto, C; Lo Russo, G; Signorelli, D; Ferrara, R; Galli, G; De Toma, A; Viscardi, G; Brambilla, M; Lobefaro, R; Nichetti, F; Manglaviti, S; Occhipinti, M; Labianca, A; Ganzinelli, M; Gallucci, R; Zilembo, N; Greco, GF; Torri, V; de Braud, F; Garassino, MC

Prelaj, A (corresponding author), Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Via Giacomo Venezian 1, I-20133 Milan, Italy.

EUROPEAN JOURNAL OF CANCER, 2021; 149 (): 235

Abstract

Background: The treatment of metastatic non-small-cell lung cancer (mNSCLC) patients with EGFR/HER2 exon 20 insertion mutation (i-mut) remains an unme......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索